| scholarly article | Q13442814 |
| P50 | author | Michel Komajda | Q64498753 |
| Dirk J van Veldhuisen | Q82060328 | ||
| Luigi Tavazzi | Q64496908 | ||
| P2093 | author name string | Philip Poole-Wilson | |
| Erland Erdmann | |||
| Pablo Lapuerta | |||
| Claude Le Pen | |||
| Nancy Hermans | |||
| José Ramon Gonzalez-Juanatey | |||
| P2860 | cites work | The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment | Q28195357 |
| The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
| Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) | Q28378044 | ||
| Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group | Q30596519 | ||
| The current cost of heart failure to the National Health Service in the UK. | Q34130575 | ||
| Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme | Q34246882 | ||
| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial | Q34246898 | ||
| The benefit of implementing a heart failure disease management program | Q34383876 | ||
| Guidelines for the diagnosis and treatment of chronic heart failure | Q34516865 | ||
| Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure | Q34753527 | ||
| Improving care for patients with chronic heart failure in the community: the importance of a disease management program | Q34844118 | ||
| Treatment of chronic heart failure with beta adrenergic blockade beyond controlled clinical trials: the BRING-UP experience | Q35581017 | ||
| Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators | Q41128429 | ||
| The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group | Q42556789 | ||
| Heart failure mortality among older Medicare beneficiaries: association with left ventricular function evaluation and angiotensin-converting enzyme inhibitor use. | Q44341807 | ||
| Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design | Q44950863 | ||
| A new approach for measuring quality of care for women with hypertension | Q46065774 | ||
| Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. | Q52905901 | ||
| Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. | Q53306482 | ||
| Ambulatory heart failure management in private practice in France | Q57605924 | ||
| P433 | issue | 16 | |
| P921 | main subject | heart failure | Q181754 |
| chronic heart failure | Q11829287 | ||
| P304 | page(s) | 1653-1659 | |
| P577 | publication date | 2005-04-12 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey | |
| P478 | volume | 26 |
| Q84597607 | A decade of developments in chronic heart failure treatment: a comparison of therapy and outcome in a secondary and tertiary hospital setting |
| Q42353999 | ACE-inhibitors, beta-blockers or the combination in heart failure: is it just an A-B-C ? : editorial to: effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al |
| Q46843313 | Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial |
| Q34076821 | Adherence to the European Society of Cardiology (ESC) guidelines for chronic heart failure--a national survey of the cardiologists in Pakistan |
| Q36077322 | Adherence to treatment guidelines in the pharmacological management of chronic heart failure in an Australian population |
| Q36811824 | Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology |
| Q35184988 | An evidence-based health workforce model for primary and community care. |
| Q36441334 | Antiarrhythmic drug therapy for atrial fibrillation: are the guidelines guiding clinical practice? |
| Q34971806 | Application of support vector machine for prediction of medication adherence in heart failure patients |
| Q93359613 | Association Between Variation in Preoperative Care Before Arterial Switch Operation and Outcomes in Patients With Transposition of the Great Arteries |
| Q36551541 | Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence |
| Q47655019 | Automating Quality Measures for Heart Failure Using Natural Language Processing: A Descriptive Study in the Department of Veterans Affairs |
| Q44166072 | Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians |
| Q88723395 | Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy |
| Q36421037 | Beta-adrenoceptor antagonists in elderly patients with chronic heart failure: therapeutic potential of third-generation agents |
| Q38170307 | Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. |
| Q45351861 | Can monitoring of intrathoracic impedance reduce morbidity and mortality in patients with chronic heart failure? Rationale and design of the Diagnostic Outcome Trial in Heart Failure (DOT-HF). |
| Q42593735 | Cardiovascular guidelines in German health care: confusion in implementation |
| Q43483340 | Cardiovascular risk profile of uncontrolled hypertensive patients. The Control-Project study |
| Q44371345 | Characteristics, implementation of evidence-based management and outcome in patients with chronic heart failure: results from the Norwegian heart failure registry |
| Q37288386 | Chronic heart failure: we are fighting the battle, but are we winning the war? |
| Q36056856 | Client factors affect provider adherence to clinical guidelines during first antenatal care |
| Q58700387 | Clinical Characteristics and Outcomes in the Very Elderly Patients Hospitalized for Acute Heart Failure: Importance of Pharmacologic Guideline Adherence |
| Q45422948 | Clinical inertia in diagnosis and treatment of hypertension in primary care: quantification and associated factors |
| Q43204655 | Clinical trials update from the Heart Failure Society of America Meeting 2009: FAST, IMPROVE-HF, COACH galectin-3 substudy, HF-ACTION nuclear substudy, DAD-HF, and MARVEL-1. |
| Q48130193 | Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey |
| Q46952191 | Comment on "Clinical trials update from the European Society of Cardiology meeting 2005: CIBIS-III, by JGF Cleland and others". |
| Q94582978 | Contemporary use of devices in chronic heart failure in the Netherlands |
| Q42245985 | Design and methodology of the COACH-2 (Comparative study on guideline adherence and patient compliance in heart failure patients) study: HF clinics versus primary care in stable patients on optimal therapy |
| Q46746456 | Design of a bilevel clinical trial targeting adherence in heart failure patients and their providers: The Congestive Heart Failure Adherence Redesign Trial (CHART). |
| Q35179984 | Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials |
| Q84337231 | Effect of a training program for primary care physicians on the optimization of beta-blocker treatment in elderly patients with heart failure |
| Q44616968 | Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial |
| Q55008819 | Effectiveness of implementation interventions in improving physician adherence to guideline recommendations in heart failure: a systematic review. |
| Q35976076 | Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol |
| Q46084737 | Effects of candesartan cilexetil "add-on" treatment in congestive heart failure outpatients in daily practice. |
| Q90259761 | Efficacy of Long-term Selenium Supplementation in the Treatment of Chronic Keshan Disease with Congestive Heart Failure |
| Q53124097 | Evidence-based healthcare, clinical knowledge and the rise of personalised medicine. |
| Q59125752 | Evolving role of pharmaceutical physicians in medical evidence and education |
| Q26858867 | Examining and addressing evidence-practice gaps in cancer care: a systematic review |
| Q39931830 | Exercise training in chronic heart failure |
| Q37857586 | Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation |
| Q46951342 | Filling the gap between guidelines and clinical practice in heart failure treatment: still a far cry from reality |
| Q38629193 | General practitioners' adherence to chronic heart failure guidelines regarding medication: the GP-HF study |
| Q33820551 | Geographic variations in heart failure hospitalizations among medicare beneficiaries in the Tennessee catchment area |
| Q40149052 | Guideline adherence for pharmacotherapy of chronic systolic heart failure in general practice: a closer look on evidence-based therapy |
| Q43454342 | Guideline compliance in the treatment of patients with chronic heart failure through family doctor-centred health care: results of an evaluation study |
| Q93160912 | Guideline-directed therapy at discharge in patients with heart failure and atrial fibrillation |
| Q42340643 | Guidelines for choosing drugs in chronic heart failure |
| Q26740285 | Heart failure across Asia: Same healthcare burden but differences in organization of care |
| Q33644701 | Heart failure in patients with coronary heart disease: Prevalence, characteristics and guideline implementation - Results from the German EuroAspire IV cohort. |
| Q30881762 | Heart failure prognosis and management in over-80-year-old patients: data from a French national observational retrospective cohort. |
| Q89172087 | Heart failure specialization in Europe |
| Q43675350 | Heart failure, aging and beta-blockers: the need for more data on tolerability and efficacy |
| Q42199698 | Heart failure: preventing disease and death worldwide |
| Q33912546 | Heart rate and functional impairment are predictors of outcome in heart failure patients in the real world. Data from the Austrian Heart Failure registry |
| Q46463401 | Hospital management of heart failure: improvement but still room for improvement at discharge... |
| Q96821482 | Hyperkalaemia and hypokalaemia outpatient management: a survey of 500 French general practitioners |
| Q40525889 | Impact of guideline adherence on mortality in treatment of left heart failure |
| Q38110451 | Implementation of a pharmacist-managed heart failure medication titration clinic |
| Q52933707 | Implementation of evidence-based therapy in patients with systolic heart failure from 1998-2000. |
| Q46098667 | Implementation of pharmacotherapy guidelines in heart failure: experience from the German Competence Network Heart Failure |
| Q36416936 | Implications of CIBIS III: a commentary |
| Q46238670 | Improved guideline adherence to pharmacotherapy of chronic systolic heart failure in general practice--results from a cluster-randomized controlled trial of implementation of a clinical practice guideline |
| Q46113736 | Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme. |
| Q34770041 | Improvement of primary care for patients with chronic heart failure: a study protocol for a cluster randomised trial comparing two strategies |
| Q46810238 | Improving care for patients with acute heart failure: before, during and after hospitalization |
| Q36743295 | Inefficacy of different strategies to improve guideline awareness - 5-year follow-up of the hypertension evaluation project (HEP) |
| Q40933167 | Influence of drug adherence and medical care on heart failure outcome in the primary care setting in Austria |
| Q37102969 | Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study |
| Q38965377 | Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction |
| Q46893322 | Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. |
| Q57315209 | Long-term follow-up in optimally treated and stable heart failure patients: primary care vs. heart failure clinic. Results of the COACH-2 study |
| Q57396286 | Medical management of advanced heart failure |
| Q92893685 | Medical therapy doses at hospital discharge in patients with existing and de novo heart failure |
| Q46033201 | Medication adherence in patients with heart failure and a depressed ejection fraction attending cardiology clinics. |
| Q30317003 | Meta-regression analyses to explain statistical heterogeneity in a systematic review of strategies for guideline implementation in primary health care |
| Q50110063 | Mind the Gap: Mismatches Between Clinicians and Patients in Heart Failure Medication Management |
| Q30539033 | Missing potential opportunities to reduce repeat COPD exacerbations |
| Q53197787 | Multidisciplinary approach for circulatory support in patients with advanced heart failure. |
| Q30725233 | Multidrug and optimal heart failure therapy prescribing in older general practice populations: a clinical data linkage study |
| Q34614873 | Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials |
| Q36815960 | Nebivolol for heart failure in the elderly |
| Q37031362 | Nebivolol in the treatment of chronic heart failure |
| Q84516283 | Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed? |
| Q33843442 | Optimized treatment and heart rate reduction in chronic heart failure |
| Q45381644 | Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups |
| Q88404572 | Palliative Care in Heart Failure |
| Q48554878 | Patient adherence to evidence-based pharmacotherapy in systolic heart failure and the transition of follow-up from specialized heart failure outpatient clinics to primary care |
| Q26778725 | Patterns in the collaboration of practitioners and researchers in the use of electrical stimulation to treat stroke patients: a literature review |
| Q34690980 | Perceived barriers of heart failure nurses and cardiologists in using clinical decision support systems in the treatment of heart failure patients |
| Q34170504 | Physician and patient predictors of evidence-based prescribing in heart failure: a multilevel study |
| Q35994392 | Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey |
| Q48656455 | Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry |
| Q92747485 | Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry |
| Q40113006 | Primary ICD-therapy in patients with advanced heart failure: selection strategies and future trials |
| Q30489956 | Primary care-based multifaceted, interdisciplinary medical educational intervention for patients with systolic heart failure: lessons learned from a cluster randomised controlled trial |
| Q85856437 | Prognostic significance of beta-blocker up-titration in conjunction with cardiac resynchronization therapy in heart failure management |
| Q46121164 | Prognostic value of heart rate variability and ventricular arrhythmias during 13-year follow-up in patients with mild to moderate heart failure |
| Q36406080 | Promise and perils of guidelines in quality cancer care |
| Q50062635 | Propensity to match or mismatch patients and therapies? |
| Q36202877 | Provider adherence to first antenatal care guidelines and risk of pregnancy complications in public sector facilities: A Ghanaian cohort study |
| Q37272793 | Public health facility resource availability and provider adherence to first antenatal guidelines in a low resource setting in Accra, Ghana |
| Q87659765 | Quality of Physician Adherence to Guideline Recommendations for Life-saving Treatment in Heart Failure: an International Survey |
| Q48372765 | Quality of medical therapy in heart failure patients undergoing elective revascularisation: A protective effect of disease modifying therapy at discharge |
| Q55003772 | Real-world heart failure management in 10,910 patients with chronic heart failure in the Netherlands : Design and rationale of the Chronic Heart failure ESC guideline-based Cardiology practice Quality project (CHECK-HF) registry. |
| Q58130030 | Reasons for Guideline Nonadherence at Heart Failure Discharge |
| Q37782417 | Reasons for non-use of proven pharmacotherapeutic interventions: systematic review and framework development. |
| Q36942081 | Regional primary care team to deliver best-practice diabetes care: a needs-driven health workforce model reflecting a biopsychosocial construct of health. |
| Q37520823 | SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World (SUGAR): a multi-center, retrospective, observational study |
| Q36109943 | Self-reported versus 'true' adherence in heart failure patients: a study using the Medication Event Monitoring System |
| Q92166998 | Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry |
| Q33471775 | Structured chronic primary care and health-related quality of life in chronic heart failure |
| Q37323953 | Successful treatment of heart failure with devices requires collaboration |
| Q57628614 | Temporal trends in epidemiology, clinical presentation and management of acute heart failure: results from the Greek cohorts of the Acute Heart Failure Global Registry of Standard Treatment and the European Society of Cardiology-Heart Failure pilot s |
| Q37016925 | The Tosca Registry: An Ongoing, Observational, Multicenter Registry for Chronic Heart Failure |
| Q43102465 | The association between long-term longitudinal trends in guideline adherence and mortality in relation to age and sex. |
| Q36837470 | The problem of polypharmacy in heart failure |
| Q40120403 | The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database |
| Q33441898 | The systematic guideline review: method, rationale, and test on chronic heart failure |
| Q38910426 | The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice |
| Q33959882 | The value of INnovative ICT guided disease management combined with Telemonitoring in OUtpatient clinics for Chronic Heart failure patients. Design and methodology of the IN TOUCH study: a multicenter randomised trial |
| Q47404445 | Transcatheter device closure of atrial septal defects: more to think about than just closing the hole |
| Q36458367 | Treatment of early heart failure: an ACEI or a beta-blocker first? |
| Q35007936 | Trends in quality of care among patients with incident heart failure in Denmark 2003-2010: a nationwide cohort study |
| Q92618929 | Use of Renin-Angiotensin-Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction |
| Q50112831 | Variation in practice patterns in device closure of atrial septal defects and patent ductus arteriosus: An analysis of data from the IMproving Pediatric and Adult Congenital Treatment (IMPACT) registry |
| Q64921118 | Variations in Practice Patterns and Consistency With Published Guidelines for Balloon Aortic and Pulmonary Valvuloplasty: An Analysis of Data From the IMPACT Registry. |
| Q44135289 | When, how and where should we "coach" patients with heart failure: the COACH results in perspective |
| Q37510745 | Why, when, and how to assess pulmonary congestion in heart failure: pathophysiological, clinical, and methodological implications |
| Q80781924 | [Compliance with hypertension therapy in Spain, according to the views of family doctors. Complex project] |
| Q83842045 | [Durability of the effects of a quality improvement intervention in hypertensive patients on long-term follow-up (CICLO-RISK study)] |
| Q80282656 | [External control in medicine. Sense or nonsense] |
| Q80079957 | [Importance of the history and the utilization of therapy guidelines in patients with arrhythmias] |
| Q81247459 | [Monitoring multiple cardiovascular paramaters using telemedicine in patients with chronic heart failure] |
| Q52616772 | [Telemonitoring in heart failure : Update on health-related and economic implications]. |
| Q82076771 | [The influence of correct blood pressure measurement on the diagnostic decisions in hypertensive patients. MEDIDA study] |
| Q79435225 | [Therapy of chronic left heart failure] |
| Q37822723 | β-blockers and their mortality benefits: underprescribed in heart failure and chronic obstructive pulmonary disease |
Search more.